Wyoming Pharmacy and Therapeutics (P&T) Committee
Public Comment Policy
(Effective 3/1/2023)

A public comment period is provided during all P&T Committee meetings. Each presenter will have a maximum of three minutes to present all oral comments to the Committee. Time allotted is at the discretion of the Committee Chair, but will not exceed three minutes.

Any handouts/written information for the Committee should be provided electronically to Aimee Lewis at alewis13@uwyo.edu at least 7 days prior to a meeting. This review time will allow the Committee to more fully incorporate the information into any recommendations or decisions made during the meeting.

Any written information not submitted as above will not be submitted to the Committee for consideration. Handouts may not be provided at the meeting. Studies which were not provided in time for Committee consideration may not be referred to in public comment.

Only published studies will be submitted to the Committee for review. Poster presentations will not be accepted in lieu of an unpublished study. Package inserts or summaries of the package insert will not be submitted for review. Speakers are asked not to present information that is readily available in the package insert or is well-known to most health care providers.

Presenters will be asked to answer the following questions during their presentation:

1. What action are you asking the Committee to take?

2. What evidence do you have to support the requested action? (ie comparative studies if you are asking for your product to be preferred with or over another agent).

3. What evidence is there that is contrary to the requested action? (ie any negative studies conducted with your product).

4. If requesting access for a particular medication, what makes this medication different from others available to treat the same condition?

All questions on page 2 must be answered. You can use this form on page 2 or copy the questions to another document. This information must be submitted following the above policy for written information at least seven days prior to the meeting. Presenters are strongly encouraged to provide published evidence to support the comments that will be made during the meeting as the Committee values this type of information. All evidence must be submitted electronically per the policy above.

If you are working with a local physician to provide comments on your medication, please refer to the general public comment policy for the appropriate public comment form.
WY P & T Committee
PhRMA Comment Request Form

Name ________________________________________________________________________________

Affiliation ____________________________________________________________________________

What action are you asking the Committee to take?

What evidence do you have to support the requested action? (ie comparative studies if you are asking for your product to be preferred with or over another agent).

What evidence is there that is contrary to the requested action? (ie any negative studies conducted with your product).

If requesting access for a particular medication, what makes this medication different from others available to treat the same condition?

Please attach all studies cited above.

By signing this form, I hereby attest that the answers given above are true, correct, complete, and not intended to mislead.

Signature and Date ________________________________________________________________________
Policy for Contacting P&T Committee Members

All contact from PhRMA representatives regarding matters directly related to the P&T Committee should be made through the DUR program at the University of Wyoming School of Pharmacy. Provision of written materials or opportunity for live presentation to the Committee may be requested by contacting Aimee Lewis, DUR Manager, at alewis13@uwyo.edu. If Committee members are approached concerning a specific Medicaid DUR issue, they may refer the representative to the DUR program.

This policy is being made in order to ensure that all Committee members are provided the same information for use in decision-making. In addition, because proceedings of the P&T Committee are public, all information provided should be made available in a public forum instead of private, one-on-one conversations.